Search Results

You are looking at 1 - 10 of 260 items for :

  • "tyrosine kinase inhibitors" x
Clear All
Full access

Merav Bar and Jerald Radich

Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia, 2012 Before the introduction of the tyrosine kinase inhibitors (TKIs), allogeneic hematopoietic cell transplantation (HCT) was the only “curative” approach for chronic myeloid

Full access

Jerald P. Radich

Conference, Dr. Radich took stock of CML in 2013, noting improvements that include multiple tyrosine kinase inhibitors (TKIs) and sensitive measures of disease burden and thus response to therapy. Transplant also remains an effective salvage regimen that is

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

years, and eventually leads to terminal blast-phase disease, with death occurring from bleeding and infectious complications. 3 First-Line Treatment: Imatinib Versus Second-Generation Tyrosine Kinase Inhibitors Imatinib Imatinib is a selective inhibitor

Full access

Helena A. Yu and Gregory J. Riely

. First-Generation EGFR Tyrosine Kinase Inhibitors Gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) that were approved for the treatment of patients with non–small cell lung cancer (NSCLC). These drugs inhibit kinase activity

Full access

Jerald P. Radich and Vivian Oehler

leukemia patients ``late,'' 18 months or more after transplantation . Blood 2001 ; 98 : 1701 – 1707 . 14. Hughes T Deininger M Hochhaus A . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma and Matthew J. Ellis

metastatic breast cancer for HER2 mutations, and treating patients with HER2-positive breast cancer with the second-generation HER2/EGFR tyrosine kinase inhibitor neratinib (HKI-272) ( ClinicalTrials.gov identifiers: NCT01670877 and NCT01953926). This

Full access

Henry J. Henk, Lena E. Winestone, Jennifer J. Wilkes, Laura Becker, Pamela Morin, Gary H. Lyman and Eric J. Chow

Background: Chronic myeloid leukemia (CML) treatment improved considerably after introduction of oral tyrosine kinase inhibitors (TKI). As a result, the number of patients living with CML may reach 250,000 by 2040. We track changes in TKI treatment

Full access

Stephen Harnicar

has not been determined. In addition to high-dose imatinib, patients now have more options for front-line therapy with the introduction of the second-generation tyrosine kinase inhibitors (TKIs). Originally approved for imatinib failure or

Full access

Jerald P. Radich

use of tyrosine kinase inhibitors (TKIs), survival in blast crisis has not clearly improved with these targeted agents. Progression to blast crisis in CML is a phenomenon that is still not completely understood. Although definitions of both

Full access

Leora Horn

progression-free survival in the EGFR mutation-positive subgroup were not apparent for overall survival. 6 Since the IPASS trial, many trials have compared EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy in the first-line treatment of patients